Sutro Biopharma (STRO) reported a Q1 loss late Thursday of $2.94 per diluted share, narrowing from a loss of $9.08 a year earlier.
Analysts surveyed by FactSet expected a loss of $2.74.
Revenue for the three months ended March 31 was $14.5 million, down from $17.4 million a year earlier.
Analysts polled by FactSet expected $8.9 million.